Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at ASH 2018

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that the clinical data for an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), alvocidib (generic name), will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 1 to 4, 2018.

For your information, the clinical data to be presented at the oral session are the stage-1 results of a phase 2 study, Zella 201, for alvocidib in patients with relapsed or refractory MCL-1-dependent Acute Myeloid Leukemia (NCT02520011).

The abstract is now available on the official website of ASH. (https://ash.confex.com/ash/2018/webprogram/start.html)

Outlook of oral presentation at the ASH 2018

<table>
<thead>
<tr>
<th>Abstract number</th>
<th>Title of oral presentation</th>
<th>Date and Time, Location</th>
<th>Study number</th>
<th>Cancer Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>#30</td>
<td>Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)</td>
<td>December 1, 2018 8:45 AM (local time), Seaport Ballroom F</td>
<td>Zella 201 (NCT02520011)</td>
<td>AML</td>
</tr>
</tbody>
</table>

(Reference)

【About inhibitor of cyclin-dependent kinase 9 (CDK9) alvocidib】
Alvocidib is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), a member of cyclin-dependent kinase family, which activates transcription of cancer-related genes. The subsequent down-regulation of MCL-1, an anti-apoptotic gene, may be responsible for the potential clinical anti-cancer activity observed with alvocidib.

【About MCL-1(Myeloid Cell Leukemia 1)】
MCL-1 is an anti-apoptotic factor.
Contact:
Public & Investor Relations Group, Corporate Governance
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)